Caroline Gaynor, Principal

Caroline joined Lightstone Ventures in 2017 with a background in Biotech and Medtech. As principal, based out of the firm’s Dublin office.

Prior to Lightstone, and following completion of her BioInnovate fellowship in 2013, she co-led R&D on a device targeting Acute Pancreatitis and was subsequently involved in early pre-clinical, strategic clinical and commercial development at Vetex Medical.

Caroline spent 9 years at Bayer Healthcare, most recently serving on the board of senior management of Bayer Ltd. Ireland as head of market access, pricing and reimbursement. During her time in pharma she held a number of operational roles, predominantly focused on oncology, such as product management, strategic marketing, business development and regulatory affairs. Prior to that, she was Scientific and Regulatory Affairs executive at the Irish Pharmaceutical Healthcare Association where she was involved in the implementation of the EU clinical trials directive. She also worked as a community pharmacist for a number of years.

Caroline serves as a director on the board of ALX Oncology Ltd. and as observer on Carrick Therapeutics, Cerevance, and FIRE-1.


B.S. in Pharmacy from Trinity College Dublin
M.S. in Pharmaceutical Medicine from Trinity College Dublin
M.S. in BioInnovation from National University of Ireland, Galway

Sector: Biopharmaceuticals, Medical Devices

Location: Dublin

Representative Investments:


See other team members.